/
WORK Medical Technology Group Ltd. is a medical technology company specializing in the manufacture and sale of disposable medical consumables and devices. Its product portfolio includes essential respiratory and anesthesia equipment such as endotracheal tubes, laryngeal mask airways, heat and moisture exchanging filters, disposable breathing circuits, nebulizer kits, and yankauer suction sets. The company also offers complementary items like medical face masks, artery compression tourniquets, endotracheal tube holders, intubating stylets, guedel airways, anesthetic kits, oxygen face masks, anesthesia masks, laryngoscope blades, nasal oxygen cannulas, KN95 masks, filtering half masks, and visualized prostatic dilatation catheters. These products support critical care procedures in hospitals and clinics worldwide. WORK Medical Technology Group Ltd. exports to approximately 30 countries across Asia, Africa, Europe, North America, South America, and Oceania, serving healthcare providers with reliable, single-use solutions that enhance patient safety and procedural efficiency. Founded in 2022 and headquartered in Hangzhou, China, it operates within the health technology sector, focusing on medical specialties.
$1.99
$0.08 (-3.86%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-9.09% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 14.4% YoY. The question is whether this is cyclical or a structural shift.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$10M
▼ -14.4% YoY
Net Income (TTM)
-$1M
▲ +66.1% YoY
Op. Margin
-9.09%
▲ +23.1pp YoY
ROIC
-2.48%
▲ +9.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$5M
▲ +142.8% YoY
Op. Cash Flow (TTM)
$6M
▲ +2126.8% YoY
Net Debt
$2M
Cash & Equiv.
$4M
3Y CAGR: -20.6%
Continue Research
Work Medical Technology Group (WOK) trades below a two-stage DCF intrinsic value of about $18,730,772.80 per share, so at $1.99 the stock looks undervalued (941,244,764.2% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Work Medical Technology Group scores 49/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $18,730,772.80 per share for WOK, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $14,048,079.60. At today's $1.99, that puts the stock about 941,244,764.2% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Work Medical Technology Group scores 49 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -9.1% operating margin and a -2.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. WOK currently trades below its estimated intrinsic value and scores 49/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.